Department of Anesthesiology and Perioperative Medicine, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, Henan, China.
Department of Nephrology, People's Liberation Army Strategic Support Force Medical Center, Beijing, China.
BMJ Open. 2022 Jul 18;12(7):e057394. doi: 10.1136/bmjopen-2021-057394.
During the COVID-19 pandemic, approximately 10%-35% of COVID-19 infected patients experience post-COVID sequela. Among these sequelae, pain symptoms should not be neglected. In addition, the sequelae of COVID-19 also decrease the quality of life of these populations. However, meta-analyses that systematically evaluated post-COVID pain are sparse.
A comprehensive screening will be performed by searching MEDLINE and Embase without language restriction from inception to August 2021. Cohort studies, case-control studies, cross-sectional studies and case series will be included. Case report and interventional studies will be excluded. Studies with less than 20 participants will be also excluded. We aim to investigate the prevalence of pain-related symptoms in patients after the acute phase of COVID-19. The impact of COVID-19 on the quality of life and pain symptoms among these populations in the post-acute phase will also be evaluated. ROBINS-I tool will be used to assess the risk of bias of cohort studies. The risk of bias tool developed by Hoy will be used to assess the risk of bias of prevalence studies. Metaprop command in Stata will be used to estimate the pooled prevalence of pain symptoms. DerSimonian and Laird random-effects models will be used to calculate the pooled relative risks. All analyses will be calculated using Stata software (V.15.0; StataCorp) ETHICS AND DISSEMINATION: Ethics approval is not required. Results of our study will be submitted to a peer-review journal.
CRD42021272800.
在 COVID-19 大流行期间，约 10%-35%的 COVID-19 感染患者会出现 COVID-19 后后遗症。在这些后遗症中，疼痛症状不容忽视。此外，COVID-19 的后遗症也降低了这些人群的生活质量。然而，系统评估 COVID-19 后疼痛的荟萃分析却很少。
我们将不限制语言，从建库至 2021 年 8 月，全面检索 MEDLINE 和 Embase 数据库。纳入队列研究、病例对照研究、横断面研究和病例系列研究。排除病例报告和干预性研究。也将排除参与者少于 20 人的研究。我们旨在调查 COVID-19 急性期后患者疼痛相关症状的患病率。还将评估 COVID-19 对这些人群在急性期后生活质量和疼痛症状的影响。我们将使用 ROBINS-I 工具评估队列研究的偏倚风险。Hoy 开发的偏倚风险工具将用于评估患病率研究的偏倚风险。我们将使用 Stata 软件（V.15.0；StataCorp）中的 Metaprop 命令估计疼痛症状的汇总患病率。我们将使用 DerSimonian 和 Laird 随机效应模型计算汇总相对风险。所有分析均将使用 Stata 软件进行计算。
不需要伦理批准。我们的研究结果将提交给同行评议期刊。
PROSPERO 注册号：CRD42021272800。
